BioCryst Pharmaceuticals Reports 33.6% Revenue Growth and $78.4M Net Income in Latest Quarter

BioCryst Pharmaceuticals, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated total revenues of $218.3 million for the quarter, a 33.6% increase from $163.4 million in the same period last year. This growth was primarily driven by a substantial rise in license and other revenues, which surged to $60.7 million from $6.5 million, largely due to the recognition of revenue from the Neopharmed License Agreement. However, product sales from ORLADEYO, its flagship drug, saw a slight increase to $158.2 million from $156.8 million, reflecting ongoing market dynamics.

In terms of profitability, BioCryst reported a net income of $78.4 million for the quarter, compared to a net income of $5.1 million in the prior year. This marked a significant turnaround, although the company recorded a net loss of $643.4 million for the six months ended June 30, 2026, primarily due to a non-cash charge of $697.8 million related to acquired in-process research and development from its merger with Astria Therapeutics. The company’s total assets increased to $557.9 million, up from $514.2 million at the end of 2025, while total liabilities rose to $1.0 billion, reflecting the impact of the merger and associated financing.

Strategically, BioCryst completed the acquisition of Astria Therapeutics on January 23, 2026, which included the lead product candidate navenibart, currently in Phase 3 clinical development for hereditary angioedema (HAE). The merger is expected to enhance BioCryst's pipeline and market position. Additionally, the company announced plans to discontinue its internal discovery programs and close its Birmingham facility, shifting focus towards external innovation and strategic partnerships to optimize resource allocation.

Operationally, BioCryst's customer base remains concentrated, with approximately 97% of ORLADEYO revenues derived from U.S. customers. The company has engaged a new specialty pharmacy for ORLADEYO shipments, aiming to streamline distribution and enhance patient access. As of June 30, 2026, BioCryst reported a total employee headcount of 255, reflecting ongoing adjustments following the merger and strategic shifts.

Looking ahead, BioCryst anticipates that its financial resources will be sufficient to fund operations for at least the next 12 months, contingent on the successful commercialization of ORLADEYO and the progression of its product candidates. The company remains focused on managing costs and exploring additional funding opportunities, including potential partnerships and licensing agreements, to support its long-term growth objectives.